Athenex Inc - ESG Rating & Company Profile powered by AI
This analysis of Athenex Inc is assembled by All Street Sevva using advanced NLP. Comprehensive ESG assessment of Athenex Inc are reached by signing in. Check the bottom of this webpage for potential risks for Athenex Inc based on sector, geography and marketcap.
Athenex Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.9; made up of an environmental score of 4.8, social score of 4.8 and governance score of 4.0.
4.9
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1047 | SQZ Biotechnologies Co | 5.0 | High |
| 1047 | Zenabis Global Inc | 5.0 | High |
| 1082 | Athenex Inc | 4.9 | High |
| 1082 | AngioLab Inc | 4.9 | High |
| 1082 | Annexon Inc | 4.9 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Athenex Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Athenex Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Athenex Inc report the average age of the workforce?
Sign up for free to unlockDoes Athenex Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Athenex Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Athenex Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Athenex Inc offer flexible work?
Sign up for free to unlockDoes Athenex Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Athenex Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Athenex Inc conduct supply chain audits?
Sign up for free to unlockDoes Athenex Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Athenex Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Athenex Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Athenex Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Athenex Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Athenex Inc disclose water use targets?
Sign up for free to unlockDoes Athenex Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Athenex Inc have a product recall in the last two years?
Sign up for free to unlockDoes Athenex Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Athenex Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Athenex Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Athenex Inc disclose parental leave metrics?
Sign up for free to unlockDoes Athenex Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Athenex Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Athenex Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Athenex Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Athenex Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Athenex Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Athenex Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Athenex Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Athenex Inc disclose its waste policy?
Sign up for free to unlockDoes Athenex Inc report according to TCFD requirements?
Sign up for free to unlockDoes Athenex Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Athenex Inc disclose energy use targets?
Sign up for free to unlockDoes Athenex Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Athenex Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Athenex Inc
These potential risks are based on the size, segment and geographies of the company.
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.